Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
May 18,2022
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.
More
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
May 06,2022
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
​Recently, the State Drug Administration approved the clinical application of XNW14010, a new class 1 anti-tumor drug from Evopoint Biosciences Co., Ltd. (hereinafter referred to as "Sinovent"), which is intended for the treatment of patients with Advanced solid tumors with KRAS G12C mutation.
More
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
May 06,2022
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
JYB1904 is a new anti-IgE recombinant humanized monoclonal antibody targeted therapy drug. IgE is the main immunoglobulin that mediates type I hypersensitivity diseases.
More
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
May 05,2022
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.
More
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
May 05,2022
Lockdown Never Stopped; Resumption of Work Increases Efficiency
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work.
More
Lockdown Never Stopped; Resumption of Work Increases Efficiency
Apr 27,2022
Medicilon was selected into the Biomedicine Index
Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.
More
Medicilon was selected into the Biomedicine Index
Apr 27,2022
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
On April 20th, the 2021 Drug Innovation Award sponsored by Securities Times, Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award.
More
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
Apr 27,2022
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
On March 9, the "Hi Liquid Workplace" 2021 China Annual Best Employer Awards Ceremony of the Yangtze River Delta region ended successfully online. Shanghai Medicilon Inc. (Medicilon) won the "Top 50 China Best Employer Award 2021."
More
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
Apr 27,2022
Medicilon was selected as a constituent stocks of the STAR 50 Index
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.
More
Medicilon was selected as a constituent stocks of the STAR 50 Index
Apr 19,2022
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Medicilon is deeply aware of its responsibilities toemployees, pharmaceutical companies and scientific research institutions, and even for the entire biopharmaceutical industry chain as an integrated prclinial R&D facility.
More
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Apr 19,2022
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Shanghai Medicilon Inc. announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon.
More
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Mar 14,2022
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Shanghai Medicilon Inc. (Medicilon) provided GLP-compliant toxicology DRF tests and application materials for the research and development of YY001, which accelerating the project to get into Phase 1 clinical trials.
More
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->